0H8I Stock Overview
Designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Accuray Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$3.05 |
| 52 Week Low | US$1.45 |
| Beta | 1.4 |
| 11 Month Change | 11.06% |
| 3 Month Change | -15.96% |
| 1 Year Change | -31.21% |
| 33 Year Change | -61.95% |
| 5 Year Change | n/a |
| Change since IPO | -65.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H8I | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 11.7% | -0.2% | 1.7% |
| 1Y | -31.2% | -2.3% | 8.3% |
Return vs Industry: 0H8I underperformed the UK Medical Equipment industry which returned -2.3% over the past year.
Return vs Market: 0H8I underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| 0H8I volatility | |
|---|---|
| 0H8I Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H8I's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0H8I's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 987 | Suzanne Winter | www.accuray.com |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Accuray Incorporated Fundamentals Summary
| 0H8I fundamental statistics | |
|---|---|
| Market cap | US$194.09m |
| Earnings (TTM) | -US$16.53m |
| Revenue (TTM) | US$444.20m |
0.4x
P/S Ratio-11.7x
P/E RatioIs 0H8I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H8I income statement (TTM) | |
|---|---|
| Revenue | US$444.20m |
| Cost of Revenue | US$306.11m |
| Gross Profit | US$138.10m |
| Other Expenses | US$154.63m |
| Earnings | -US$16.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 31.09% |
| Net Profit Margin | -3.72% |
| Debt/Equity Ratio | 376.4% |
How did 0H8I perform over the long term?
See historical performance and comparison